Should you buy Henry Schein (HSIC)?
Updated
Three consecutive earnings beats suggest improving execution, but the stock is trading above its near-term price target with RSI at 81 and weak underlying growth — the current entry geometry favors waiting for a pullback before committing new capital.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Three of the last four quarters produced positive earnings surprises ranging from 3% to 8%, suggesting improving execution consistency following a miss in the oldest reported quarter. Earnings | Beat rate maintains 3 of 4 over the next four quarters, with average EPS surprise above 3%. | →Stable |
| CounterThe oldest quarter in the trailing record was a 7.6% miss, and revenue growth is weak; if pricing or volume trends in the distribution business deteriorate, the beat streak could reverse without a clearly defensible operational moat. | ||
The stock is trading above its near-term price target with negative upside and a deeply unfavorable risk/reward ratio — meaning even a moderate pullback would erode more value than the target offers in reward. Price targets | A better entry appears only if the stock corrects to create at least 10% headroom to the near-term target. | →Stable |
| CounterRising on-balance volume and a positive MACD suggest accumulation is continuing; if the next quarterly result surprises to the upside, the target could reset higher and re-open the economics for new capital. | ||
Free cash flow represents only 73% of reported net income, a conversion shortfall that deserves scrutiny for a medical distribution business where earnings should translate closely to cash. Quality breakdown | Free cash flow conversion rises above 90% of net income for 2 consecutive reported periods. | →Stable |
| CounterThe Piotroski F-Score is a strong 8 out of 9, indicating solid overall financial health; the below-par conversion may reflect working capital dynamics rather than a structural quality deficit. | ||
Three of the last four quarters produced positive earnings surprises ranging from 3% to 8%, suggesting improving execution consistency following a miss in the oldest reported quarter.
→Stable- Expectation
- Beat rate maintains 3 of 4 over the next four quarters, with average EPS surprise above 3%.
CounterThe oldest quarter in the trailing record was a 7.6% miss, and revenue growth is weak; if pricing or volume trends in the distribution business deteriorate, the beat streak could reverse without a clearly defensible operational moat.
The stock is trading above its near-term price target with negative upside and a deeply unfavorable risk/reward ratio — meaning even a moderate pullback would erode more value than the target offers in reward.
→Stable- Expectation
- A better entry appears only if the stock corrects to create at least 10% headroom to the near-term target.
CounterRising on-balance volume and a positive MACD suggest accumulation is continuing; if the next quarterly result surprises to the upside, the target could reset higher and re-open the economics for new capital.
Free cash flow represents only 73% of reported net income, a conversion shortfall that deserves scrutiny for a medical distribution business where earnings should translate closely to cash.
→Stable- Expectation
- Free cash flow conversion rises above 90% of net income for 2 consecutive reported periods.
CounterThe Piotroski F-Score is a strong 8 out of 9, indicating solid overall financial health; the below-par conversion may reflect working capital dynamics rather than a structural quality deficit.
▸ Show 1 more pillar▾ Show fewer
Weak growth is explicitly flagged as a concern, and the absence of an identifiable competitive moat makes it difficult to justify patience at a forward multiple of 13.7x without a clear acceleration catalyst.
→Stable- Expectation
- Growth concerns ease if EPS actuals exceed $1.50 for 2 consecutive quarters, signaling a meaningful step-up from the current run rate.
CounterA PEG of 1.78 is not extreme for a healthcare distribution franchise, and if the beat cadence continues at even modest magnitudes, the multiple could look inexpensive relative to a recovering growth trajectory.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Three of the last four quarters produced positive earnings surprises ranging from 3% to 8%, suggesting improving execution consistency following a miss in the oldest reported quarter.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2The stock is trading above its near-term price target with negative upside and a deeply unfavorable risk/reward ratio — meaning even a moderate pullback would erode more value than the target offers in reward.
Trip ifUpside to the price target exceeds 10% from the prevailing market price.
- P3Free cash flow represents only 73% of reported net income, a conversion shortfall that deserves scrutiny for a medical distribution business where earnings should translate closely to cash.
Trip ifFree cash flow conversion rises above 90% of net income for 2 consecutive reported quarters.
- P4Weak growth is explicitly flagged as a concern, and the absence of an identifiable competitive moat makes it difficult to justify patience at a forward multiple of 13.7x without a clear acceleration catalyst.
Trip ifEPS actuals exceed $1.50 for 2 consecutive quarters.
How the engine reached this verdict
TrendMatrix's engine output for Henry Schein, Inc. (HSIC) is SELL_IF_HOLDING with medium conviction, score 5.0/10 at $83.88. The F-path SELL output reflects an overall score of 5.0 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of -0.50 is supplementary context, not the trigger.
The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:6.7>=5.5.
On the bull side: Strong earnings beat streak (3/4). On the bear side: Analyst target reached - limited upside remaining; Weak growth. Active engine warnings: V8: Target reached (-5.5% upside), V9 Gate Failed: ASYMMETRY:-0.5=NEGATIVE.
The engine's exit framework anchors to a tactical sell band near $83.88, with structural invalidation at $80.05. The asymmetric R:R against a reversal hypothesis is 3.26 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates HSIC — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
Bear case
- ▸Analyst target reached - limited upside remaining
- ▸Weak growth